Report on the Cellicium Meeting Heidelberg 25 Janvier 2005 Contents List of participants... 2 1. The Cellicium project in relation with SANOFI's interest... 2. Presentation of the project management by VITAMIB... 3. Relevance of the chosen associated companies for the new Cellicium project... 4. Distribution of the partners of the project in each workgroup... 5. Presentation of the 2 STREPs... 6. Partners of the 2 STREPs... 7. Proposed list of new workpackages in relation to SANOFI... 8. Schedule for the project... 3 3 4 5 7 9 10 11 1
List of participants NAME Firstname Institution / Lab Mail ADELH Didier Samba Technologies dadelh@sambatechnologies.com BAHRAMI Diane CEA Paris diane.bahrami@cea.fr BARILLOT Emmanuel Institut Curie, Paris Emmanuel.Barillot@curie.fr BARLOVATZ Georgia INSERM U492, Créteil barlovatz@creteil.inserm.fr CABIN Armelle Univ. Rouen armelle.cabin@univ-rouen.fr CARL Christian Kip Heidelberg carlcc@kip.uni-heidelberg.de COHEN Olivier TIMC, Grenoble Olivier.Cohen@imag.fr CREMER Christoph KIP Heidelberg cremer@kip.uni-heidelberg.de DEMONGEOT Jacques TIMC, Grenoble Jacques.Demongeot@imag.fr EILS Juergen DKFZ, Heidelberg j.eils@dkfz-heidelberg.de EILS Roland DKFZ, Heidelberg eils@iwr.uni-heidelberg.de FRANCOISE Jean-Pierre Univ. Pierre et Marie Curie, Paris 6 jpf@moka.ccr.jussieu.fr GALLOIS Jean-Pierre CEA Paris jean-pierre.gallois@cea.fr GIROUD Françoise TIMC, Grenoble Francoise.Giroud@imag.fr GRANGEAT Pierre LETI, CEA Grenoble pierre.grangeat@cea.fr LANCET Doron Weizmann Institute of Science, Rehovot doron.lancet@weizmann.ac.il LESNE Annick Lab. Phys. Théor. Des Liquides, Paris lesne@lptl.jussieu.fr MACHAULT Vanessa Vitamib vmachault@vitamib.com MARTIN BATTLE Ramon Samba Technologies rmartibatlle@sambatechnologies.com MATTES Julian UMIT, Hall julian.mattes@umit.at MOLINA Franck Inst. De Biotech. et Pharm. Montpellier franck.molina@ibph.pharma.univ-montp1.fr PEYRIERAS Nadine ENS Paris peyriera@wotan.ens.fr REISS Thomas Fraunhofer ISI, Karlsruhe Thomas.Reiss@isi.fhg.de STEPHANOU Angélique TIMC, Grenoble Angelique.Stephanou@imag.fr 2
1 The Cellicium project in relation with SANOFI's interest The pharmaco-genetics loop defined in relation with SANOFI AVENTIS as the main industrial partner of the Cellicium Project. 2 Presentation of the project management by VITAMIB See associated documents Appendix A: VITAMIB Presentation Appendix B: Integrated project Cellicium Guidelines for the proposal construction 3
3 Relevance of the chosen associated companies for the new Cellicium project Company's Name Size Location Associated keywords Name of cellicium contact Sanofi-Aventis *** Big Paris 4 11 J. Demongeot Bioret *** Start-up Evry 7 F. Képès Biomax Middle Munich 5 J.Eils Eurogentech Middle Brussel 5 MP Lefranc HC Forum Big Grenoble 4 11 J. Demongeot Leica Big Mannheim 4 11 C. Carl Samba *** Middle Grenoble 4 11 J. Demongeot Wany (#) Middle Montpellier 7 F. Molina Helios (#) Start-up Paris 5 G. Barlovatz Aureus Pharma (#) Middle Paris 6 10 M. Roux-Rouquié Isoft (#) Middle Orsay 10 P. Amar Tripath (#) Middle Grenoble 4 J. Demongeot ATOS (*) Middle Madrid 1 P. Marche TASCON (*) Start-up Munster 4 12 P. Grangeat WIZSOFT (*) Start-up Tel-Aviv 1 5 P. Marche BIOPREDIC (*) Middle Rennes 4 5 P. Marche ORYZON GENOMICS (*) Middle Madrid 1 4 P. Marche *** Leader companies for the Cellicium project (#) Companies which can rather be associated to the STREPs (*) Companies mainly concerned with Immunology (their involvement will depend on the choice of SANOFI as a major actor in the Cellicium project) Comments: - Biomax: integration tools for genomic data - Leica: not doing a lot of image analysis development - Samba: strongly involved in image processing softwares - Helios: data modelling, data mining, regulation network modelling - Isoft: tools for data integration but not for knowledge modelling - Tripath: softwares on image pathologies, depends on SAMBA 4
4 Distribution of the partners of the project in each work group Computer Science and Modelling Community (Groupe 1) University of Leicester (GB) UMIT Innsbruck (A) CEA (LIST/LETI) (F) University of Heidelberg (IPMB, KIP, IWR) (D) IHES (F) University of Rouen Institut Curie (F) CNRS (Montpellier, Evry, Génoscope, TIMC, Paris 6, Paris 12) (F) Basel (CH) Karlsruhe (D) Trieste (I) Data and Knowledge Bases (Groupe 2) Swiss Prot (CH) IMGT (F) Genecards (IL) CNRS (TIMC) (F) Institut Curie (LRI, Orsay),Ecole des Mines (F) Prague (CZ) Data Providers (Groupe 3) DKFZ (D) Institut Curie (F) University of Rouen (F) University of Heidelberg (D) Université Libre de Bruxelles (B) CEA (LETI) (F) ENS (F) INSERM (F) LMU (D) Heraklion (G) Budapest (H) Krakaw (P) Karolinska (S) Partners associated to the IP Other partners in the IP 5
Summary Austria (A) Belgium(B) 13 countries 20 Institutions / Teams in the IP Czech Republic(CZ) France (F) Germany (D) Greece (G) Hungary (H) Israel (IL) Italy (I) Poland (P) United-Kingdom (GB) Sweden (S) Switzerland (CH) UMIT Innsbruck Université Libre de Bruxelles Prague CEA CNRS IMGT INSERM Institut Curie University of Rouen DKFZ Karlsruhe University of Heidelberg Heraklion Budapest Genecards Trieste Krakaw University of Leicester Karolinska Swiss Prot 6
5 Presentation of the 2 STREPs STREP 1 E-morfos: Cell proliferation and migration in embryogenesis and neogenesis Main Scientific Focus Invasion strategies: individual vs collective behaviour, emergence of collective displacement and migration coupling of cytoskeleton reaction-diffusion processes and mechanical forces modulation with regulatory metabolic and signaling networks. Mechanical constraints, morphological changes and cell proliferation adhesion, tension gravity genetic regulation in space and time at the multicellular level as a response to microenvironment changes Individual migration (consequences of subcellular events + microenvironment fluctuations) physiopathological conditions: wound healing physiological conditions: embryogenesis pathological conditions: cancerogenesis, invasion Collective displacement (consequence of individual behaviour + interactions) physiopathological conditions: wound healing physiological conditions: embryogenesis pathological conditions: cancerogenesis, invasion At each level a team of theoreticians can be associated 7
STREP 2: Malicom Inverse problems in Biomedicine 8
6 Partners of the 2 STREPs UMIT Innsbruck (A) E-MORFOS (STREP 1) 14 teams, 6 countries DKFZ (D) EMBL (D) LMU (D) University of Heidelberg (D) ENS (F) LRI (F) Paris 12 (F) University of Rouen (F) TIMC (F) UCL (Stern) (GB) Bologna (I) Trieste (I) MALICOM (STREP 2) 12 teams, 6 countries Université Libre de Bruxelles (B) Basel (CH) IWR (D) Genecards (IL) CAMS/CREA (F) CEA (LIST) (F) CNRS (TIMC) (F) IHES (F) Institut Curie / Ecole des Mines (F) LRI (F) Oxford University (Maini) (GB) University of Leicester (GB) Slovaquia (Sl) 9
7 Proposed list of new Workpackages in relation to SANOFI The revised pharmaco-genetic loop (SANOFI) Proposed Workpackages WP1: Collection of the patient record (clinical information) Deliverable: The Cellicium patient records WP2: Data acquisition from gene to tissue Deliverable: The Cellicium data acquisition protocol WP3: Data and knowledge integration Deliverable: The Cellicium knowledge integrator WP4: Data exploration from gene to tissue (data mining) Deliverable: The Cellicium data mining protocol WP5: Modelling for prediction (prognosis and drug power prediction) Providing tools for therapy development Deliverable: The Cellicium prediction protocol WP6: Training WP7: Management 10
8 Schedule for the Project DEADLINES IST First Call: 22 March 2005 IST Second Call: 15 September 2005 MEETINGS IP Meetings 14-15 February 2005 Meeting at the Institut Curie, Paris 18-20 March 2005 Meeting in Grenoble, finalization of the project STREPs Meeting 18-23 April 2005 Cargèse Workshop on STREPs Strategy (IST-FET Call 5) (Scientific Meeting) 11